Ma Rui
Partner @ Frees Fund
Ma Rui is a seed investor at Frees Fund focused on Health Care and Semiconductor. Ma Rui is the partner of Fengrui Capital.
- Total investments:
- 5
- Last investment:
- Lead investor:
- 40%
Last updated:
For AI agents: llms.txt
Industries Ma Rui invests in
Stages Ma Rui invests in
Countries Ma Rui invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 1 (20%)
- Semiconductor 1 (20%)
- Machine Learning 1 (20%)
- Health Diagnostics 1 (20%)
- Artificial Intelligence 1 (20%)
Stage
- Seed 1 (20%)
- Angel 1 (20%)
- Series A 1 (20%)
Country
- China 1 (20%)
- United States 1 (20%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
|
Zhuma Innovation
|
Zhuma Innovation offers 3D reconstruction services of consumer quality. It focuses on consumer-grade 3D reconstruction and spatial intelligence, offering a new class of 3DGS cameras and developing the next generation of spatial imaging terminals, all supported by 3DGS (3D Gaussian Splash) core technology. | Angel / May 25, 2026 | |
|
Zhuma Innovation
|
Zhuma Innovation offers 3D reconstruction services of consumer quality. It focuses on consumer-grade 3D reconstruction and spatial intelligence, offering a new class of 3DGS cameras and developing the next generation of spatial imaging terminals, all supported by 3DGS (3D Gaussian Splash) core technology. | Angel / Mar 23, 2026 | |
|
Ningkang Ruizhu
|
Ningkang Ruizhu is a targeted drugs developer. | $14.1M / Series A / Dec 05, 2025 | |
| We are a development stage startup enabling the next generation of precision medicine by fusing biochip and AI technologies. | $14.1M / Seed / Jul 31, 2023 | ||
| N1 Life is an innovative biomedical company that focused on drug discovery and development of PDC drugs in the anti-tumor pipeline. | $10M / Seed / Apr 17, 2023 |
Co-Investors
About Frees Fund
By adopting revolutionary mechanisms, FREES FUND is devoted to change the long-established rules in the venture capital. By leveraging the cutting-edge technologies and resources, FREES FUND aims at investing in great startups and helping them grow into great enterprises that are valuable to our society. We mainly invest in early-stage startups, and hope to become their first-round institutional investor. Our primary interested areas are broad-sense TMT (Technology, Media, Telecom), B2B and deep technology.
Frees Fund Contacts
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Ma Rui invest in?
Ma Rui invests primarily in Health Care, Semiconductor and Machine Learning startups, most often at Seed and Angel stage. Most of the 5 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Ma Rui?
For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Ma Rui last invest?
The most recent investment recorded for Ma Rui closed in May 2026. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
